Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2

• Change from baseline in plaque psoriasis as assessed by PASI response or PASI 50 (a patient that has an improvement from baseline PASI of at least 50%) [ Time Frame: to 8 weeks treatment ] [ Designated as safety issue: No ]
• Change from baseline in plaque psoriasis as assessed by PASI response or PASI 90 (a patient that has an improvement from baseline PASI of at least 90%) [ Time Frame: to 8 weeks treatment ] [ Designated as safety issue: No ]
• Laboratory parameters, rates of AEs, and percentage of patients requiring interruption or discontinuation of study drug due to AEs [ Time Frame: to 8 weeks treatment ] [ Designated as safety issue: Yes ]

The purpose of this study is to determine whether Triptergium wilfordii, and Acitretin are effective and safe in the treatment of patient of moderate to severe psoriasis vulgaris.

• Drug: Triptergium Wilfordii
  Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
• Drug: Acitretin
  Capsule,10mg/Cap,30mg Qd,no more than 8 weeks

• Active Comparator: Triptergium Wilfordii
  a kind of traditional chinese medicine
  Intervention: Drug: Triptergium Wilfordii
• Active Comparator: Acitretin
  Intervention: Drug: Acitretin

Inclusion Criteria:

• Adults of both sexes, between the age 18 and 75 years.
• Have a diagnosis of psoriasis vulgaris,PASI score of 7 or greater.
• Capable of giving informed consent and the consent must be obtained prior to any study related procedures.

Exclusion Criteria:

• Currently have erythrodermic,guttate or pustular psoriasis.
• Have any active dermatoses which may affect disease assessment of psoriasis.
• Have used any investigational drug,any biologic or any systemic immunosuppressants within the previous 1 month..
• Have used topical medications/treatments that could affect psoriasis or PASI evaluation (eg, corticosteroids, tar, phototherapy et al.) within 2 weeks.
• Have any acute or chronic or recurrent infectious disease,which was difficult to control.
• Have the history of HBV or HCV infection,or HIV antibody test positive.
• AST, ALT or blood fat levels must be within 1.5 times the ULN range for the laboratory conducting the test.
• Are pregnant, nursing, or planning pregnancy in the coming two years(both men and women) while enrolled in the study.
• Have any severe systemic disease or have a history of malignancy.
• Have shown a previous hypersensitivity to Triptergium wilfordii or Acitretin.
• Have any other condition not suitable to join in trial,which are judged by investigator.